Data gathered: May 11
AI Stock Analysis - Karyopharm Therapeutics (KPTI)
Analysis generated April 23, 2025. Powered by Chat GPT.
Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel, first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. The company's lead product candidate, selinexor, has potential applicability in various oncology indications and represents a significant advancement in the field of cancer therapeutics. Karyopharm's innovative approach in targeting nuclear export pathways distinguishes it from traditional cancer therapies, giving it a competitive edge in the biopharmaceutical market.
Stock Alerts - Karyopharm Therapeutics (KPTI)
 |
Karyopharm Therapeutics | May 9 Price is up by 8.1% in the last 24h. |
|
Karyopharm Therapeutics | May 8 Insider Alert: Paulson Richard A. is selling shares |
|
Karyopharm Therapeutics | May 6 Price is down by -9.6% in the last 24h. |
|
Karyopharm Therapeutics | May 6 Business Outlook among employees is up by 4% over the last month. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Karyopharm Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 4 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 86 | Sign up | Sign up | Sign up |
| Google Trends | 9 | Sign up | Sign up | Sign up |
| Patents | 31 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 16 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,822 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,545 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 78 | Sign up | Sign up | Sign up |
| Linkedin Employees | 360 | Sign up | Sign up | Sign up |
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases.
| Price | $6.01 |
| Target Price | Sign up |
| Volume | 62,640 |
| Market Cap | $52M |
| Year Range | $3.54 - $14.85 |
| Dividend Yield | 0% |
| Analyst Rating | 83% buy |
| Earnings Date | May 12 '25 |
| Industry | Biotechnology |
In the news
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1 - Finnhub |
|
 |
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Here’s What HappenedApril 10 - ETF Daily News |
|
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below 200 Day Moving Average – Time to Sell?March 25 - ETF Daily News |
|
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Time to Sell?March 11 - ETF Daily News |
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025May 8 - Finnhub |
|
 |
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumoursMay 2 - The BMJ |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 31M | 1.3M | 29M | -31M | -20M | -0.240 |
| Q3 '24 | 39M | 1.3M | 37M | -32M | -21M | -0.257 |
| Q2 '24 | 43M | 1.6M | 41M | 24M | 33M | 0.150 |
| Q1 '24 | 33M | 2M | 31M | -37M | -31M | -0.320 |
| Q4 '23 | 34M | 1.6M | 32M | -42M | -35M | -0.360 |
Insider Transactions View All
| Paulson Richard A. filed to sell 82,503 shares at $7.1. May 7 '25 |
| Rangwala Reshma filed to sell 28,853 shares at $6.2. April 24 '25 |
| Paulson Richard A. filed to sell 82,739 shares at $3.7. April 7 '25 |
| Abate Kristin filed to sell 9,713 shares at $6.3. March 6 '25 |
| Mano Michael filed to sell 21,047 shares at $6.3. March 6 '25 |
Similar companies
Read more about Karyopharm Therapeutics (KPTI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Karyopharm Therapeutics?
The Market Cap of Karyopharm Therapeutics is $52M.
When does Karyopharm Therapeutics report earnings?
Karyopharm Therapeutics will report its next earnings on May 12 '25.
What is the current stock price of Karyopharm Therapeutics?
Currently, the price of one share of Karyopharm Therapeutics stock is $6.01.
How can I analyze the KPTI stock price chart for investment decisions?
The KPTI stock price chart above provides a comprehensive visual representation of Karyopharm Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Karyopharm Therapeutics shares. Our platform offers an up-to-date KPTI stock price chart, along with technical data analysis and alternative data insights.
Does KPTI offer dividends to its shareholders?
As of our latest update, Karyopharm Therapeutics (KPTI) does not offer dividends to its shareholders. Investors interested in Karyopharm Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Karyopharm Therapeutics?
Some of the similar stocks of Karyopharm Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.